Fight CRC Clinical Trial Finder
NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
---|---|---|---|---|---|---|---|---|---|
NCT ID NCT04362839 |
TitleRegorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2020-04-27 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃,非招募
|
药物
Ipilimumab, Nivolumab, Regorafenib, Opdivo, Stivarga, Yervoy |
标签
MSS/ MMRp
|
NCT ID NCT04110093 |
Title瑞戈非尼加 PD-1 抑制剂治疗结直肠癌患者 | 阶段
第 1 阶段/第 2 阶段
|
Date Added 2019-10-01 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
瑞戈非尼和 PD-1 抑制剂 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT06006923 |
TitleRegorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | 阶段
第二阶段
|
Date Added 2023-08-23 |
地点
California, United States
Florida, United States Illinois, United States Pennsylvania, United States Washington, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Pembrolizumab, Regorafenib, Keytruda, Stivarga |
标签
MSI-H/ MMRd
|
NCT ID NCT06456515 |
TitleRegorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRC | 阶段
不适用
|
Date Added 2024-06-13 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSS/ MMRp
|
NCT ID NCT03657641 |
TitleRegorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2018-09-05 |
地点
California, United States
Florida, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃,非招募
|
药物
Pembrolizumab, Regorafenib, Keytruda, Stivarga |
标签
MSS/ MMRp
|
NCT ID NCT04626635 |
TitleREGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors | 阶段
Phase 1, Phase 2
|
Date Added 2020-11-12 |
地点
California, United States
Florida, United States Illinois, United States Iowa, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States 法国 以色列 荷兰 波兰 西班牙 Turkey |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
cemiplimab, REGN7075 |
标签
MSS/ MMRp
|
NCT ID NCT03388632 |
Title重组白细胞介素-15 与检查点抑制剂 Nivolumab 和 Ipilimumab 联合治疗难治性癌症患者 | 阶段
第 1 阶段
|
Date Added 2018-01-03 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Ipilimumab, Nivolumab, rhIL-15, Opdivo, Yervoy |
标签
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT05785325 |
TitleRC48-ADC 联合贝伐单抗治疗 HER2 阳性晚期结直肠癌 | 阶段
第二阶段
|
Date Added 2023-03-27 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
RC48-ADC 加贝伐单抗 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT05292417 |
TitleRadiotherapy in Combination With Sintilimab,GM-CSF and Fruquintinib in Patients With MSS mCRC | 阶段
第二阶段
|
Date Added 2022-03-23 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Fruquintinib, GM-CSF, Sintilimab |
标签
MSS/ MMRp
|
NCT ID NCT04050709 |
TitleQUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers | 阶段
第 1 阶段
|
Date Added 2019-08-08 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃,非招募
|
药物
PD-L1 t-haNK |
标签
MSS/ MMRp
|